C14orf178 Inhibitors
C14orf178 inhibitors encompass a spectrum of chemicals that employ diverse molecular mechanisms to attenuate the functional activity of C14orf178 within cellular signaling networks. The inhibition strategies range from direct enzyme inhibition to interference with signaling and metabolic pathways that indirectly regulate the activity of C14orf178. Some compounds achieve inhibition by binding to and altering the activity of kinases that are pivotal in signaling pathways, such as the PI3K/AKT and MAPK/ERK cascades, which are integral to processes involving cell growth, survival, and proliferation. These inhibitors prevent phosphorylation events necessary for the propagation of signals that C14orf178 may be enhancing, thus curtailing its influence on the cell. Other inhibitors disrupt cellular energy homeostasis by impeding glucose transport, which could indirectly lead to the downregulation of C14orf178-related functions by depriving cells of the energy required for these processes.
Additionally, the inhibitors target various other aspects of cellular regulation that could be associated with the functional activity of C14orf178. Some chemicals inhibit the proteasome, leading to an accumulation of proteins that regulate the cell cycle, potentially modifying the regulatory roles C14orf178 may have. Others obstruct the activity of kinases involved in cytoskeleton organization, which could affect cell structure and motility, processes that C14orf178 might be influencing. Inhibition of receptor tyrosine kinases, which are often the starting point for numerous signaling pathways, also serves to dampen the cellular responses that could be potentiated by C14orf178.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Targets the mTOR pathway by binding to FKBP12 and forming a complex that inhibits the mTORC1 complex, which in turn regulates protein synthesis and cell growth. Inhibition of mTORC1 would downregulate processes that are potentially upregulated by C14orf178. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinase inhibitor that blocks PI3K signaling, thereby reducing AKT phosphorylation and downstream signaling that might be enhanced by C14orf178. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Specifically inhibits the phosphorylation and activation of Akt, which could be part of the signaling cascade influenced by C14orf178, leading to its functional inhibition. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
Inhibits glucose transporter 1 (GLUT1), which may decrease glycolytic activity. Reduced energy production from glycolysis could inhibit cellular processes in which C14orf178 is implicated. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor which prevents the activation of MAPK/ERK pathway, potentially downregulating the cellular responses that C14orf178 may be involved in promoting. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor which can suppress inflammation and apoptosis pathways that C14orf178 might be involved in, leading to decreased activity of C14orf178. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits the JNK signaling pathway, which could be responsible for modulating transcription factors and other cellular processes that C14orf178 might influence. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Inhibits ROCK kinase which is involved in actin cytoskeleton organization. As C14orf178 may be associated with cellular structure maintenance, its inhibition could affect C14orf178 related processes. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
Inhibits BMP signaling pathway which might interplay with pathways that C14orf178 is part of, leading to its decreased activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that can prevent the degradation of regulatory proteins that control cell cycle, growth, and apoptosis, influencing any regulatory roles played by C14orf178. | ||||||